SEC Filing Analysis: UNITED THERAPEUTICS Corp (UTHR)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Founder, Chairperson, and CEO of United Therapeutics, Martine Rothblatt, has filed a notice of proposed sale for 4,000 shares valued at approximately $1.75 million. This transaction is part of a pre-established 10b5-1 trading plan.
• Market Impact: Neutral. The transaction size is immaterial relative to the company's $19.18 billion market capitalization.

Company Information

Field	Value
Company	UNITED THERAPEUTICS Corp
Ticker Symbol	UTHR
CIK	0001082554
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	ROTHBLATT MARTINE A
CIK	0001106578
Title/Position	FOUNDER, CHAIRPERSON, AND CHIEF EXECUTIVE OFFICER
Relationship	Officer

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-11-03 (Approximate)
Transaction Code	Not Applicable (Form 144 Proposed Sale)
Security Type	COMMON
Shares Involved	4,000
Price Per Share	$438.30 (approximate)
Total Value	$1,753,194
Shares Owned After	Not Disclosed
Ownership Type	Not Disclosed

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$1,753,194
% of Market Cap	0.009%
Shares Transacted	4,000
% of Shares Outstanding	0.009%
Post-Transaction Ownership	Not Disclosed
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a large-cap company with a market capitalization of $19.18 billion, a $1.75 million transaction is considered routine and financially insignificant.
• Transaction Significance: The sale represents a negligible percentage of both market cap and shares outstanding, falling far below the thresholds for moderate or high significance. The impact on the public float is minimal.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is minor and executed under a pre-disclosed 10b5-1 plan, which reduces its signaling value. The market typically does not react to such small, planned sales from long-tenured executives.

Volume & Sentiment

• Expected Volume Impact: Negligible. The 4,000 shares will be easily absorbed by the market without a noticeable impact on trading volume.
• Sentiment Indicator: Neutral. This is viewed as a standard liquidity event for the executive, not a bearish signal on the company's future prospects.

Additional Context

Special Circumstances

• 10b5-1 Plan: The filing notes a plan adoption date of May 2, 2025. This indicates the sale was pre-scheduled, providing an affirmative defense against claims of trading on non-public information.
• Sale History: The filing discloses a lengthy history of similar-sized sales by the same insider throughout September and October 2025, reinforcing the routine nature of these transactions.